AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
Go back to AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi| (NASDAQ: ABCL) | Delayed: 12.63 -0.1 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.73 | 52 Week High | $ | |||
| Open | $12.73 | 52 Week Low | $ | |||
| Day High | $12.96 | P/E | N/A | |||
| Day Low | $12.37 | EPS | $ | |||
| Volume | 5,437,651 | |||||
